1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Jun 2020
Admin
News Article

Union Health Ministry Issues Updated Clinical Management Protocol For Managing Covid-19 Cases

Keeping Pace With Evolving Knowledge About Covid-19, Especially In Terms Of Effective Drugs, The Union Health Ministry Has Released An Updated Clinical Management Protocol For Managing Covid-19 Cases.The Updated Protocol Includes The Advice To Use Dexamethasone As An Alternative Choice To Methylprednisolone For Managing Moderate To Severe Cases Of Covid-19. The Change Has Been Made After Considering The Latest Available Evidence And Expert Consultation.Dexamethasone Is A Corticosteroid Drug Used In A Wide Range Of Conditions For Its Anti-Inflammatory And Immunosuppressant Effects.The Drug Has Been Tested In Hospitalized Patients With Covid-19 In The Recovery Clinical Trial And Was Found To Have Benefits For Critically Ill Patients And Has Been Shown To Reduce Mortality By About One Third For Patients On Ventilators, And By About One Fifth For Patients Being Maintained On Oxygen Therapy. The Drug Is Also A Part Of The National List Of Essential Medicines (Nlem) And Is Widely Available.The Union Health Secretary, Preeti Sudan Has Forwarded The Updated Protocol With All States/Uts To Make Necessary Arrangements For Availability And Use Of The Updated Protocol And Drug Dexamethasone At The Institutional Level Also

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!